$MCET Patents by Assignee Multicell Immunotherapeutics, Inc.
METHODS AND FORMULATIONS TO ACHIEVE TUMOR TARGETED DOUBLE STRANDED RNA MEDIATED CELL DEATH Publication number: 20140335154 Abstract: A composition having double stranded ribonucleic acid (dsRNA) molecules is provided. The composition induces tumor cell death or suppresses tumor growth. The double stranded RNA molecules contain equal to or less than 15 base pairs. Methods for delivery of the composition are also disclosed. Type: Application Filed: March 12, 2014 Publication date: November 13, 2014 Applicant: MULTICELL IMMUNOTHERAPEUTICS, INC. Inventor: Simona Bot
Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells Patent number: 8809290 Abstract: The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-?, IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process. Type: Grant Filed: April 1, 2011 Date of Patent: August 19, 2014 Assignee: Multicell Immunotherapeutics, Inc. Inventors: Adrian Bot, Lilin Wang, Dan Joseph Smith, William Joseph Phillips, Jr., Luis A. Dellamary
Compositions and methods to treat and control tumors Publication number: 20120189645 Abstract: The present application is directed to non-coding RNA motifs that are used in conjunction with an antigen or without an antigen to induce, enhance or modulate an immune response that compromises a B cell and a T cell component. Type: Application Filed: February 18, 2010 Publication date: July 26, 2012 Applicant: Multicell immunotherapeutics, Inc. (Formally ASTRAL, INC.) Inventors: Adrian Bot, Lilin Wang, Luis Dellamary, Dan Smith, Bill Phillips
SELECTED MA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS Publication number: 20090169571 Abstract: The present application is directed to the use of dsRNA and/or ssRNA for the purpose of inducing apoptosis or cell death in proliferating cells. Specifically, low molecular weight and high molecular weight dsRNA and ssRNA are shown to induce apoptosis and/or cell death in proliferating cells, to arrest proliferation of transformed cells or tumor cells and to cause rapid induction of the cytokine TNF-alpha and/or also induce production of IL-12 which directs a Th-1 response. Type: Application Filed: November 14, 2008 Publication date: July 2, 2009 Applicant: Multicell Immunotherapeutics, Inc. Inventors: Dan Smith, Adrian Bot
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.